

PetCure Oncology Clinical Trials

Driving clinical innovation - for pets and people

Stereotactic radiation (SRS/SRT) may be a standard treatment option in human oncology, but it is still relatively new for pets with cancer. PetCure Oncology is committed to clinical trials that will further our understanding of cancer and cancer therapy in pets - and improve both the quantity and quality of life for pets with cancer.

The thousands of pets treated by PetCure Oncology since 2015 also offer a unique opportunity for translational research. By analyzing the results of every treatment and partnering with our peers on the human side of cancer care and research, every PetCure treatment contributes to improving the lives of both pets and people.

Clinical Trial Enrollment

If you have questions or would like to refer an animal for evaluation/inclusion into one of our clinical trials, contact:

*Brandy Banks, RT(R)(T)
Clinical Trials Coordinator
PetCure Oncology
ClinicalTrials@PetCureOncology.com
844.308.2578*

[PetCureOncology.com/ClinicalTrials](https://www.petcureoncology.com/ClinicalTrials)

Currently Open Clinical Trials (as of 9/9/19)

SRS/SRT & Immune Activation*

PREMISE: Early data collected by PetCure Oncology as well as other investigators suggests that SRS/SRT in dogs may have a positive effect on the immune cells responsible for attacking cancer, leading to longer survival times than a traditional treatment course centered around surgical tumor removal. One hypothesis for this is that SRS/SRT not only treats the primary tumor, but may also modulate the anti-tumor immune response in a manner that inhibits the spread of the cancer. The purpose of this trial is to test this theory.

ELIGIBILITY: Dogs undergoing SRS/SRT to treat **osteosarcoma, oral malignant melanoma, sino-nasal tumors, or thyroid carcinoma**, all of which are known to have metastatic potential.

REQUIREMENTS: Participation in a total of four (4) pre- and post-treatment blood draws.

COMPENSATION: Pet owners will receive \$2,000 towards their treatment. All trial-related blood draws will be free of charge.

Lung Tumors

PREMISE: SRS/SRT is already a standard of care for people with primary lung tumors. Surgical removal of these tumors can be invasive. With multiple critical organs nearby, it can also be difficult to treat with conventional radiation therapy, which is less precise than SRS/SRT. This trial will test the hypothesis that SRS/SRT is a safe and effective way to treat dogs with lung tumors.

ELIGIBILITY: Dogs with solitary and presumed primary lung tumors that have not spread to other parts of the body.

REQUIREMENTS: Subsidized SRS/SRT treatment followed by CT scans at 3- and 12-months post-treatment.

COMPENSATION: Participating pet owners will benefit from heavily subsidized SRS/SRT treatment at a discount of up to \$5,250 (varies by center). Two-week recheck appointment and CT scans at 3- and 12-months post treatment will be free of charge.

The Immune Activation trial is a joint project between PetCure Oncology and **varian Medical Systems.*

